Additional file 2: Table S1. of Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy

Dose changes and dose delays by treatment arm. Table S2. Adverse events leading to study drug discontinuation regardless of study drug relationship. Table S3. Study center. (DOCX 17 kb)